To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024.
Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EM
Bavarian Nordic will get an accelerated review of its chikungunya vaccine CHIKV VLP at the EMA, as it tries to chase down a lead held by rival Valneva.
An artificial intelligence-powered computer-aided detection (CAD) system developed by Israeli medtech company Magentiq-Eye has been shown to improve detection rates for ad
When two or more people from the world of medical technology meet, talk inevitably turns to the ongoing, yet elusive, search for an industry-standard, multi-disciplinary diagnostic device –
Views & Analysis
White Papers & Webinar
Podcasts & Video
The industry has been calling for a disease-agnostic event fully dedicated to the exciting new modality of peptide-based drugs.
A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place
According to the FDA, 2024 will be the ’breakout year’ for gene therapies.
In the dynamic cell therapy landscape, where financial challenges continue to prevail, the emphasis on innovative process development becomes pivotal.